These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 16278397)

  • 1. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
    J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.
    Moreno C; Villamor N; Colomer D; Esteve J; Martino R; Nomdedéu J; Bosch F; López-Guillermo A; Campo E; Sierra J; Montserrat E
    J Clin Oncol; 2005 May; 23(15):3433-8. PubMed ID: 15809449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
    Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
    N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.
    Zenz T; Döhner H; Stilgenbauer S
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):439-53. PubMed ID: 17707832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
    Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
    Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
    Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
    Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
    Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
    N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
    Kusenda J; Babusíková O
    Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
    Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
    Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
    Pavletic SZ; Khouri IF; Haagenson M; King RJ; Bierman PJ; Bishop MR; Carston M; Giralt S; Molina A; Copelan EA; Ringdén O; Roy V; Ballen K; Adkins DR; McCarthy P; Weisdorf D; Montserrat E; Anasetti C
    J Clin Oncol; 2005 Aug; 23(24):5788-94. PubMed ID: 16043827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.